- Home
- QURE vs DYN Comparison
QURE vs DYN Comparison
Compare QURE & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | DYN |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | Netherlands | United States |
| Employees | 248 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | QURE | DYN |
|---|---|---|
| Price | $22.42 | $15.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 17 |
| Target Price | ★ $61.24 | $35.73 |
| AVG Volume (30 Days) | 2.5M | ★ 2.9M |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.67 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,107,000.00 | N/A |
| Revenue This Year | $54.78 | N/A |
| Revenue Next Year | $356.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.73 | $14.00 |
| 52 Week High | $71.50 | $27.31 |
Technical Indicators
Market Signals| Indicator | QURE | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 28.08 | 41.20 |
| Support Level | $22.32 | $14.43 |
| Resistance Level | $25.61 | $19.46 |
| Average True Range (ATR) | 1.19 | 0.88 |
| MACD | 0.75 | 0.29 |
| Stochastic Oscillator | 57.58 | 45.28 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.